Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Frédéric Bigot et al.|Molecular Cancer Therapeutics|2023Cited by 60
Charting the future of marine biotechnology: educational strategies for empowering Europe’s blue bioeconomy workforceMarija Kataržytė, Stéphanie Bordenave-Juchereau, Susana P. Gaudêncio et al.|Frontiers in Marine Science|2026Cited by 0